Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 20 systematic review(s)/meta-analysis(es). ^[1-20]
• Chronic Graft-versus-Host Disease (cGVHD): Ibrutinib demonstrated an overall response rate (ORR) of 54%-78% in pediatric patients and 67%-76% in adult patients, offering long-lasting responses with manageable side effects.
• Chronic Lymphocytic Leukemia (CLL): In real-world settings, patients treated with ibrutinib exhibited 12-month overall survival rates of 95%-96% and 18-month overall survival rates of 91%, along with progression-free survival (PFS) rates ranging from 89%-93%.
• Waldenstrom Macroglobulinaemia (WM): The combination of ibrutinib and rituximab (IR) achieved a pooled response rate of 26% and a two-year PFS of 82%, which was lower than the response rates of bendamustine-rituximab (46%) and bortezomib-dexamethasone-cyclophosphamide-rituximab (33%).
• Uncommon EGFR Mutations: Ibrutinib showed significant effectiveness in patients with high-risk genomic features in CLL, reinforcing its role as a treatment option for patients with del(17p), del(11q), and unmutated IGHV status.
• Infection Risk: Ibrutinib was associated with a significantly increased risk of infections in patients with B-cell malignancies, with a pooled risk ratio of 1.34 for any grade infections and 1.35 for grade 3-5 infections.
• Bleeding Incidence: The use of ibrutinib significantly raised the risk of overall bleeding (RR=2.56) and major bleeding (RR=2.08), particularly noted in patients with Chronic Lymphocytic Leukemia (CLL).
• Adverse Effects in Chronic Graft-versus-Host Disease (cGVHD): Common adverse effects for patients treated with ibrutinib included pyrexia, diarrhea, abdominal pain, cough, nausea, and other symptoms, indicating a broad range of manageable side effects.
• The studies included patients with B-cell malignancies, such as Chronic Lymphocytic Leukemia (CLL) and Waldenstrom Macroglobulinaemia (WM), as well as pediatric and adult populations with Chronic Graft-versus-Host Disease (cGVHD); ibrutinib demonstrated a high overall response rate (ORR) of 54%-78% in pediatric and 67%-76% in adult patients with cGVHD, indicating effective treatment across age groups and manageable side effects.